Public University Corporation Nara Medical University

Chugai Seiyaku Kabushiki Kaisha

Sysmex Corporation

Sekisui Medical Co., Ltd.

Nara Medical University

Midori Shima

Keiji Nogami

Takehisa Kitazawa

Tetsuhiro Soeda

Tomoko Matsumoto

Hiroshi Kurono

Tsukasa Suzuki

Toshiki Kawabe

Sho Shinohara

Nobuo Arai

Yuka Ikeda

Yuka Tabuchi

Masahiro Takeyama

Kenichi Ogiwara

To provide a method for analyzing coagulation characteristics of a blood specimen. To provide a method for analyzing a blood specimen, including: acquiring a waveform related to a coagulation rate or coagulation acceleration of a sample obtained by mixing a subject blood specimen with a reagent for measuring coagulation time; extracting multiple parameters characterizing the waveform related to a coagulation rate or a coagulation acceleration; and determining an activity level or activity abnormality of a coagulation factor in the subject blood specimen on the basis of the multiple parameters.

Method for analyzing blood coagulation characteristics of blood specimen

Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.

Method for analyzing blood specimen, reagent and reagent kit for analyzing blood specimen, and blood specimen analyzer

The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.

Method for measuring reactivity of FVIII

Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.

Method for evaluating blood coagulation reaction

The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.

Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein

Disclosed is a blood sample determination method including: emitting light to a measurement specimen prepared by mixing a clotting time measuring reagent and a blood sample suspected to be derived from a subject having lupus anticoagulant or a coagulation factor inhibitor, to obtain optical information about an amount of light from the measurement specimen; obtaining at least one parameter regarding derivative of clot waveform, based on the obtained optical information; and determining, based on a value of the obtained parameter, whether the blood sample is suspected to be a sample derived from a subject having lupus anticoagulant or is suspected to be a sample derived from a subject having a coagulation factor inhibitor.

Blood sample determination method and blood sample analyzer

For the first time, the present invention provides antibodies that enhance the generation of activated blood coagulation factor VIII. The antibodies enhance the cleavage of blood coagulation factor VIII at the Arg of position 372 and suppress the cleavage at the Arg of position 336 by recognizing and binding to the A2 domain of blood coagulation Factor VIII. Such antibodies are expected to be useful in preventing or treating diseases that develop or progress due to decrease or loss of the blood coagulation factor VIII activity, for example, hemophilia A, acquired hemophilia, and von Willebrand's disease.

Growing community of inventors

Kashihara, Japan

Midori Shima